Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fulcrum Therapeutics (FULC) Restructuring Costs (2022 - 2024)

Fulcrum Therapeutics (FULC) has disclosed Restructuring Costs for 2 consecutive years, with $2.1 million as the latest value for Q3 2024.

  • Quarterly Restructuring Costs changed N/A to $2.1 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $2.1 million through Dec 2025, changed 0.0% year-over-year, with the annual reading at $2.1 million for FY2024, N/A changed from the prior year.
  • Restructuring Costs for Q3 2024 was $2.1 million at Fulcrum Therapeutics, up from -$38000.0 in the prior quarter.
  • The five-year high for Restructuring Costs was $2.1 million in Q3 2024, with the low at -$38000.0 in Q4 2022.